Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...
Two pharma giants are squaring off a first-of-a-kind lawsuit over the budding biosimilar business in the U.S. Unable to make much headway with its first biosimilar rollout, Pfizer accuses Johnson & ...
Johnson & Johnson’s Remicade, which remains one of the world’s best-selling drugs, is one step closer to facing competition after a FDA advisory committee voted 21-3 in support of approving a ...
New York City-based Pfizer will start shipping its biosimilar copy of Johnson & Johnson’s best-selling arthritis drug Remicade in November, offering the drug at a 15 percent discount, according to ...
Remicade comes as a powder. A healthcare professional mixes the powder with liquid to form a solution, which they give as an intravenous (IV) infusion. (This is an injection into a vein given over ...
A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results